{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:12:29Z","timestamp":1791616349816,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["RO1-HL121253"],"award-info":[{"award-number":["RO1-HL121253"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["RO1-HL122421"],"award-info":[{"award-number":["RO1-HL122421"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1F30-HL140878"],"award-info":[{"award-number":["1F30-HL140878"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001873"],"award-info":[{"award-number":["UL1TR001873"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM007367"],"award-info":[{"award-number":["T32 GM007367"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Methods"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41592-020-00992-6","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T17:05:16Z","timestamp":1604941516000},"page":"1245-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-8858","authenticated-orcid":false,"given":"Scott A.","family":"Kanner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunaira","family":"Shuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papiya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2340-8899","authenticated-orcid":false,"given":"Henry M.","family":"Colecraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"992_CR1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev-neuro-060909-153122","volume":"33","author":"DM Kullmann","year":"2010","unstructured":"Kullmann, D. M. Neurological channelopathies. Annu. Rev. Neurosci. 33, 151\u2013172 (2010).","journal-title":"Annu. Rev. Neurosci."},{"key":"992_CR2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1152\/physrev.00008.2016","volume":"97","author":"MS Bohnen","year":"2016","unstructured":"Bohnen, M. S. et al. Molecular pathophysiology of congenital long QT syndrome. Physiol. Rev. 97, 89\u2013134 (2016).","journal-title":"Physiol. Rev."},{"key":"992_CR3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","volume":"16","author":"GR Cutting","year":"2014","unstructured":"Cutting, G. R. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat. Rev. Genet. 16, 45\u201356 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"992_CR4","doi-asserted-by":"crossref","first-page":"660\u2013669","DOI":"10.1038\/nrendo.2013.166","volume":"9","author":"FM Ashcroft","year":"2013","unstructured":"Ashcroft, F. M. & Rorsman, P. KATP channels and islet hormone secretion: new insights and controversies. Nat. Rev. Endocrinol. 9, 660\u2013669 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"992_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2016.00121","volume":"7","author":"P Imbrici","year":"2016","unstructured":"Imbrici, P. et al. Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery. Front. Pharmacol. 7, 121 (2016).","journal-title":"Front. Pharmacol."},{"key":"992_CR6","doi-asserted-by":"crossref","unstructured":"Wulff, H., Christophersen, P., Colussi, P., Chandy, G. K. & Yarov-Yarovoy, V. Antibodies and venom peptides: new modalities for ion channels. Nat. Rev. Drug Discov. 18, 339\u2013357 (2019).","DOI":"10.1038\/s41573-019-0013-8"},{"key":"992_CR7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.hrthm.2005.01.020","volume":"2","author":"DJ Tester","year":"2005","unstructured":"Tester, D. J., Will, M. L., Haglund, C. M. & Ackerman, M. J. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2, 507\u2013517 (2005).","journal-title":"Heart Rhythm"},{"key":"992_CR8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cardiores.2005.04.036","volume":"67","author":"AJ Wilson","year":"2005","unstructured":"Wilson, A. J., Quinn, K. V., Graves, F. M., Bitner-Glindzicz, M. & Tinker, A. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc. Res. 67, 476\u2013486 (2005).","journal-title":"Cardiovasc. Res."},{"key":"992_CR9","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1074\/jbc.274.31.21873","volume":"274","author":"M Haardt","year":"1999","unstructured":"Haardt, M., Benharouga, M., Lechardeur, D., Kartner, N. & Lukacs, G. L. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J. Biol. Chem. 274, 21873\u201321877 (1999).","journal-title":"J. Biol. Chem."},{"key":"992_CR10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","volume":"63","author":"SH Cheng","year":"1990","unstructured":"Cheng, S. H. et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827\u2013834 (1990).","journal-title":"Cell"},{"key":"992_CR11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-physiol-021014-071838","volume":"77","author":"J Curran","year":"2015","unstructured":"Curran, J. & Mohler, P. J. Alternative paradigms for ion channelopathies: disorders of ion channel membrane trafficking and posttranslational modification. Annu. Rev. Physiol. 77, 505\u2013524 (2015).","journal-title":"Annu. Rev. Physiol."},{"key":"992_CR12","doi-asserted-by":"crossref","first-page":"eaar2631","DOI":"10.1126\/sciadv.aar2631","volume":"4","author":"H Huang","year":"2018","unstructured":"Huang, H. et al. Mechanisms of KCNQ1 channel dysfunction in long QT syndrome involving voltage sensor domain mutations. Sci. Adv. 4, eaar2631 (2018).","journal-title":"Sci. Adv."},{"key":"992_CR13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00012.2016","volume":"97","author":"N Foot","year":"2017","unstructured":"Foot, N., Henshall, T. & Kumar, S. Ubiquitination and the regulation of membrane proteins. Physiol. Rev. 97, 253\u2013281 (2017).","journal-title":"Physiol. Rev."},{"key":"992_CR14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrd2056","volume":"5","author":"G Nalepa","year":"2006","unstructured":"Nalepa, G., Rolfe, M. & Harper, W. J. Drug discovery in the ubiquitin\u2013proteasome system. Nat. Rev. Drug Discov. 5, 596\u2013613 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"992_CR15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/cr.2016.31","volume":"26","author":"X Huang","year":"2016","unstructured":"Huang, X. & Dixit, V. M. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 26, 484\u2013498 (2016).","journal-title":"Cell Res."},{"key":"992_CR16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cardiores.2007.01.008","volume":"74","author":"T Jespersen","year":"2007","unstructured":"Jespersen, T. et al. The KCNQ1 potassium channel is down-regulated by ubiquitylating enzymes of the Nedd4\/Nedd4-like family. Cardiovasc. Res. 74, 64\u201374 (2007).","journal-title":"Cardiovasc. Res."},{"key":"992_CR17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2013.05.046","volume":"154","author":"T Mevissen","year":"2013","unstructured":"Mevissen, T. et al. OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell 154, 169\u2013184 (2013).","journal-title":"Cell"},{"key":"992_CR18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1074\/mcp.M700342-MCP200","volume":"7","author":"U Rothbauer","year":"2008","unstructured":"Rothbauer, U. et al. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol. Cell. Proteomics 7, 282\u2013289 (2008).","journal-title":"Mol. Cell. Proteomics"},{"key":"992_CR19","doi-asserted-by":"crossref","first-page":"ra22","DOI":"10.1126\/scisignal.2005025","volume":"7","author":"GW Abbott","year":"2014","unstructured":"Abbott, G. W. et al. KCNQ1, KCNE2, and Na+-coupled solute transporters form reciprocally regulating complexes that affect neuronal excitability. Sci. Signal. 7, ra22 (2014).","journal-title":"Sci. Signal."},{"key":"992_CR20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cvr\/cvu231","volume":"104","author":"AS Aromolaran","year":"2014","unstructured":"Aromolaran, A. S., Subramanyam, P., Chang, D. D., Kobertz, W. R. & Colecraft, H. M. LQT1 mutations in KCNQ1 C-terminus assembly domain suppress IKs using different mechanisms. Cardiovasc. Res. 104, 501\u2013511 (2014).","journal-title":"Cardiovasc. Res."},{"key":"992_CR21","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1074\/jbc.M806459200","volume":"284","author":"D Peroz","year":"2009","unstructured":"Peroz, D., Dahim\u00e8ne, S., Bar\u00f3, I., Loussouarn, G. & M\u00e9rot, J. LQT1-associated mutations increase KCNQ1 proteasomal degradation independently of Derlin-1. J. Biol. Chem. 284, 5250\u20135256 (2009).","journal-title":"J. Biol. Chem."},{"key":"992_CR22","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1016\/j.bmcl.2012.07.060","volume":"22","author":"ME Mattmann","year":"2012","unstructured":"Mattmann, M. E. et al. Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective Kv7.1 (KCNQ1) potassium channel activator. Bioorg. Med. Chem. Lett. 22, 5936\u20135941 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"992_CR23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit, G. et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol. Biol. Cell 27, 424\u2013433 (2016).","journal-title":"Mol. Biol. Cell"},{"key":"992_CR24","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","volume":"4","author":"K Boeck","year":"2016","unstructured":"Boeck, K. & Amaral, M. D. Progress in therapies for cystic fibrosis. Lancet Respir. Med. 4, 662\u2013674 (2016).","journal-title":"Lancet Respir. Med."},{"key":"992_CR25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright, C. E. et al. Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med. 373, 220\u2013231 (2015).","journal-title":"N. Engl. J. Med."},{"key":"992_CR26","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Goor","year":"2011","unstructured":"Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl Acad. Sci. USA 108, 18843\u201318848 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"992_CR27","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Goor","year":"2009","unstructured":"Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106, 18825\u201318830 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"992_CR28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/febs.13531","volume":"283","author":"CM Farinha","year":"2016","unstructured":"Farinha, C. M. & Matos, P. Repairing the basic defect in cystic fibrosis\u2014one approach is not enough. FEBS J. 283, 246\u2013264 (2016).","journal-title":"FEBS J."},{"key":"992_CR29","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.chembiol.2011.10.017","volume":"18","author":"AC Faesen","year":"2011","unstructured":"Faesen, A. C. et al. The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chem. Biol. 18, 1550\u20131561 (2011).","journal-title":"Chem. Biol."},{"key":"992_CR30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","volume":"169","author":"F Liu","year":"2017","unstructured":"Liu, F., Zhang, Z., Csan\u00e1dy, L., Gadsby, D. C. & Chen, J. Molecular structure of the human CFTR ion channel. Cell 169, 85\u201395 (2017).","journal-title":"Cell"},{"key":"992_CR31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41594-018-0028-6","volume":"25","author":"C McMahon","year":"2018","unstructured":"McMahon, C. et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat. Struct. Mol. Biol. 25, 289\u2013296 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"992_CR32","doi-asserted-by":"crossref","first-page":"C1734\u2013C1742","DOI":"10.1152\/ajpcell.2001.281.5.C1734","volume":"281","author":"LV Galietta","year":"2001","unstructured":"Galietta, L. V., Jayaraman, S. & Verkman, A. S. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am. J. Physiol. Cell Physiol. 281, C1734\u2013C1742 (2001).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"992_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","volume":"15","author":"AG Durmowicz","year":"2018","unstructured":"Durmowicz, A. G., Lim, R., Rogers, H., Rosebraugh, C. J. & Chowdhury, B. A. The U.S. Food and Drug Administration\u2019s experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial. Ann. Am. Thorac. Soc. 15, 1\u20132 (2018).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"992_CR34","doi-asserted-by":"crossref","unstructured":"Han, S. T. et al. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators. JCI Insight 3, e121159 (2018).","DOI":"10.1172\/jci.insight.121159"},{"key":"992_CR35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","volume":"13","author":"F Goor","year":"2014","unstructured":"Goor, F., Yu, H., Burton, B. & Hoffman, B. J. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 13, 29\u201336 (2014).","journal-title":"J. Cyst. Fibros."},{"key":"992_CR36","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"992_CR37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molmed.2011.10.003","volume":"18","author":"GL Lukacs","year":"2012","unstructured":"Lukacs, G. L. & Verkman, A. S. CFTR: folding, misfolding and correcting the \u0394F508 conformational defect. Trends Mol. Med. 18, 81\u201391 (2012).","journal-title":"Trends Mol. Med."},{"key":"992_CR38","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1191542","volume":"329","author":"T Okiyoneda","year":"2010","unstructured":"Okiyoneda, T. et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805\u2013810 (2010).","journal-title":"Science"},{"key":"992_CR39","unstructured":"Sigoillot, M. et al. Domain-interface dynamics of CFTR revealed by stabilizing nanobodies. Nat. Commun. 10, 2636 (2019)."},{"key":"992_CR40","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1091\/mbc.e04-11-1010","volume":"16","author":"SM Kreda","year":"2005","unstructured":"Kreda, S. M. et al. Characterization of wild-type and \u0394F508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol. Biol. Cell 16, 2154\u20132167 (2005).","journal-title":"Mol. Biol. Cell"},{"key":"992_CR41","doi-asserted-by":"crossref","first-page":"e57617","DOI":"10.1371\/journal.pone.0057617","volume":"8","author":"MA van Meegen","year":"2013","unstructured":"van Meegen, M. A., Terheggen-Lagro, S. W., Koymans, K. J., van der Ent, C. K. & Beekman, J. M. Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis. PLoS ONE 8, e57617 (2013).","journal-title":"PLoS ONE"},{"key":"992_CR42","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fphar.2018.01100","volume":"9","author":"R Fukuda","year":"2018","unstructured":"Fukuda, R. & Okiyoneda, T. Peripheral protein quality control as a novel drug target for CFTR stabilizer. Front. Pharmacol. 9, 1100 (2018).","journal-title":"Front. Pharmacol."},{"key":"992_CR43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/35050509","volume":"3","author":"GC Meacham","year":"2001","unstructured":"Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M. & Cyr, D. M. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. 3, 100\u2013105 (2001).","journal-title":"Nat. Cell Biol."},{"key":"992_CR44","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/01.RES.0000128561.28701.ea","volume":"94","author":"BP Delisle","year":"2004","unstructured":"Delisle, B. P. et al. Biology of cardiac arrhythmias. Circ. Res. 94, 1418\u20131428 (2004).","journal-title":"Circ. Res."},{"key":"992_CR45","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949\u2013963 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"992_CR46","doi-asserted-by":"crossref","unstructured":"Kanner, S. A., Morgenstern, T. & Colecraft, H. M. Sculpting ion channel functional expression with engineered ubiquitin ligases. eLife 6, e29744 (2017).","DOI":"10.7554\/eLife.29744"},{"key":"992_CR47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nsmb.2180","volume":"19","author":"E Caussinus","year":"2011","unstructured":"Caussinus, E., Kanca, O. & Affolter, M. Fluorescent fusion protein knockout mediated by anti-GFP nanobody. Nat. Struct. Mol. Biol. 19, 117\u2013121 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"992_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00043-6","author":"A Mullard","year":"2019","unstructured":"Mullard, A. First targeted protein degrader hits the clinic. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/d41573-019-00043-6 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"992_CR49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41594-020-0438-0","volume":"27","author":"T Wu","year":"2020","unstructured":"Wu, T. et al. Targeted protein degradation as a powerful research tool in basic biology and drug target discovery. Nat. Struct. Mol. Biol. 27, 605\u2013614 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"992_CR50","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4161\/cbt.10.8.13417","volume":"10","author":"D Shi","year":"2010","unstructured":"Shi, D. & Grossman, S. R. Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol. Ther. 10, 737\u2013747 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"992_CR51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.chom.2009.05.012","volume":"5","author":"MK Isaacson","year":"2009","unstructured":"Isaacson, M. K. & Ploegh, H. L. Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 5, 559\u2013570 (2009).","journal-title":"Cell Host Microbe"},{"key":"992_CR52","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nmeth.3170","volume":"11","author":"PC Fridy","year":"2014","unstructured":"Fridy, P. C. et al. A robust pipeline for rapid production of versatile nanobody repertoires. Nat. Methods 11, 1253\u20131260 (2014).","journal-title":"Nat. Methods"},{"key":"992_CR53","doi-asserted-by":"crossref","first-page":"17114","DOI":"10.1073\/pnas.0407563101","volume":"101","author":"Y Sekine-Aizawa","year":"2004","unstructured":"Sekine-Aizawa, Y. & Huganir, R. L. Imaging of receptor trafficking by using \u03b1-bungarotoxin-binding-site-tagged receptors. Proc. Natl Acad. Sci. USA 101, 17114\u201317119 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"992_CR54","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.molcel.2009.09.043","volume":"36","author":"S Gao","year":"2009","unstructured":"Gao, S. et al. Ubiquitin ligase Nedd4L targets activated Smad2\/3 to limit TGF-\u03b2 signaling. Mol. Cell 36, 457\u2013468 (2009).","journal-title":"Mol. Cell"},{"key":"992_CR55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-1-61779-120-8_20","volume":"742","author":"KW Peters","year":"2011","unstructured":"Peters, K. W. et al. CFTR folding consortium: methods available for studies of CFTR folding and correction. Methods Mol. Biol. 742, 335\u2013353 (2011).","journal-title":"Methods Mol. Biol."},{"key":"992_CR56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0014-5793(01)02561-3","volume":"499","author":"LJ Galietta","year":"2001","unstructured":"Galietta, L. J., Haggie, P. M. & Verkman, A. S. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett. 499, 220\u2013224 (2001).","journal-title":"FEBS Lett."},{"key":"992_CR57","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1165\/rcmb.2016-0276MA","volume":"56","author":"M Gentzsch","year":"2017","unstructured":"Gentzsch, M. et al. Pharmacological rescue of conditionally reprogrammed cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 56, 568\u2013574 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"992_CR58","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.celrep.2018.09.072","volume":"25","author":"C Zhang","year":"2018","unstructured":"Zhang, C. et al. Long-term in vitro expansion of epithelial stem cells enabled by pharmacological inhibition of PAK1\u2013ROCK\u2013Myosin II and TGF-\u03b2 signaling. Cell Rep. 25, 598\u2013610 (2018).","journal-title":"Cell Rep."},{"key":"992_CR59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36735-z","volume":"9","author":"RE Rayner","year":"2019","unstructured":"Rayner, R. E., Makena, P., Prasad, G. L. & Cormet-Boyaka, E. Optimization of normal human bronchial epithelial (NHBE) cell 3D cultures for in vitro lung model studies. Sci. Rep. 9, 500 (2019).","journal-title":"Sci. Rep."},{"key":"992_CR60","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3389\/fphys.2018.00397","volume":"9","author":"SA Kanner","year":"2018","unstructured":"Kanner, S. A., Jain, A. & Colecraft, H. M. Development of a high-throughput flow cytometry assay to monitor defective trafficking and rescue of long QT2 mutant hERG channels. Front. Physiol. 9, 397 (2018).","journal-title":"Front. Physiol."},{"key":"992_CR61","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.celrep.2016.02.077","volume":"14","author":"S-R Lee","year":"2016","unstructured":"Lee, S.-R., Sang, L. & Yue, D. T. Uncovering aberrant mutant PKA function with flow cytometric FRET. Cell Rep. 14, 3019\u20133029 (2016).","journal-title":"Cell Rep."}],"container-title":["Nature Methods"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41592-020-00992-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41592-020-00992-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41592-020-00992-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:11:28Z","timestamp":1684620688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41592-020-00992-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1038\/s41592-020-00992-6","relation":{},"ISSN":["1548-7091","1548-7105"],"issn-type":[{"value":"1548-7091","type":"print"},{"value":"1548-7105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.K. and H.M.C. have filed a patent application through Columbia University based on this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}